Elutia (ELUT) Cantor Global Healthcare Conference 2025 summary

Company overview and product focus

• Specializes in drug-eluting biologics, combining biological matrices with active pharmaceuticals to improve patient outcomes in implantable devices.

• EluPro, the lead product, is a biologic envelope for pacemakers and defibrillators, offering antibiotic protection and tissue integration.

• EluPro has FDA approval and commercial launch, with strong early sales and a partnership with Boston Scientific to accelerate growth.

• Expansion into breast reconstruction with NXT-41X, a drug-eluting biologic targeting a large unmet need and market opportunity.

• Focused on scaling proven technology into new indications and markets.

Market dynamics and competitive positioning

• U.S. pacemaker protection market is valued at $600 million, previously dominated by a single plastic-based competitor.

• EluPro differentiates with a biological matrix, appealing to device makers outside Medtronic and offering superior patient outcomes.

• Boston Scientific partnership drives about 30% of sales, with significant pull-through effect in accounts.

• Surgeons show strong preference for EluPro over older plastic-based products, though Medtronic's bundling slows conversion.

• Company leverages GPO contracts and direct sales to accelerate hospital adoption.

Commercialization and growth strategy

• Currently in 161 active accounts, adding 12–15 new VAC approvals monthly, aiming for 1,600 target centers.

• Growth is a scaling exercise, with predictable ordering once VAC approval is secured.

• Boston Scientific and GPO support expected to accelerate account penetration beyond current rates.

• Gross margin improved from mid-50s% to low 60s%, with further leverage expected as production scales and testing is internalized.

• EluPro projected to reach $18–20 million run rate by year-end, with continued acceleration anticipated.